We report the identi®cation of a novel human tumor associated gene, CDCP1 (Cub Domain Containing Protein), which was identi®ed using representational dierence analysis and cDNA chip technology. The gene consists of eight exons, the upstream region of which neither contains a TATA-nor a CCAAT-box. However, a CpG island is located around the transcription start, which is found in approximately 60% of known genes. The CDCP1 gene was mapped to chromosome 3p21-p23 by¯uorescence in situ hybridization. For expression pro®ling real time quantitative RT ± PCR was performed using cell lines and laser capture microdissected colon cancer biopsies. CDCP1 mRNA is approximately 6 kb and highly overexpressed in human colon cancer and lung cancer. CDCP1 represents a putative transmembrane protein, containing three CUB domains in the extracellular part most likely involved in cell adhesion or interacting with the extracellular matrix. Oncogene (2001) 20, 4402 ± 4408.
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Cancer is a genetic disease that involves clonal evolution of transformed cells (Fialkow, 1976; Nowell, 1976) resulting from an accumulation of mutations either inherited (germline) or acquired (somatic), in critical proto-oncogenes and tumor suppressor genes. Each mutation may provide additional growth advantage to the transformed cell as they dominate their normal counterparts (Fearon and Vogelstein, 1990; Sidransky et al., 1992 ). Changes in the transcriptional level of genes in cancer tissues can lead to upregulation of proteins; understanding these changes may provide the basis to de®ne new targets for therapeutical interventions. Various methods are available for detecting and quantifying gene expression levels (To, 2000) , including serial analysis of gene expression (SAGE) (Velculescu et al., 1995; Ishii et al., 2000; Stollberg et al., 2000; Parle-McDermott et al., 2000) , dierential display (Liang and Pardee, 1992), representational dierence analysis (RDA) (Hubank and Schatz, 1994; Diatchenko et al., 1996; Hubank and Schatz, 1999) , and cDNA chip technology (Brown and Botstein, 1999; Afshari et al., 1999; Kurian et al., 1999) .
In this study we describe the use of RDA to identify dierentially regulated genes in cancer compared to normal tissue. Using A549 (ATCC: CCL-185), a human lung cancer cell line, as tester and normal lung as driver for subtraction approximately 700 clones were ampli®ed exponentially, subcloned into vectors, sequenced and annotated with bioSCOUT TM (Lion Bioscience). Half of the clones coded for genes with known function, the rest gave no signi®cant hits to sequences in public data bases and in an eort to further investigate these ESTs all of them were arrayed on glass slides together with selected IMAGE clones of known genes (Figure 1 ).
It is known that a number of genes have similar functions in dierent types of solid tumors. In an attempt to identify such`tumor associated genes', consistently upregulated within solid tumors, we performed cDNA chip hybridizations using a variety of dierent tumor types.
Interestingly DNA chip analysis demonstrated that some ESTs are not only signi®cantly expressed in human lung carcinomas but are even higher expressed in cell lines derived from colon carcinomas ( Figure  1a ,b). EST 1, EST 2 and EST 3 gave similar transcription patterns and subsequently were revealed to be partially overlapping (EST 2 and EST 3 are not shown). The alignment resulted in a consensus sequence of 843 bp and was designated CUB Domain Containing Protein 1, CDCP1.
The BLAST algorithm (Altschul et al., 1997 ) was used to search for EST homologues in the dbest database. Several ESTs (AA357574, AI862284, M77904, etc.) were found, which expanded the sequence information from 843 bp to approximately 1500 bp. The full-length sequence was ampli®ed as demonstrated in Figure 2 . DNA containing a portion of the promoter region for the human CDCP1 gene was isolated using a human Promoter Finder DNA Oncogene (2001) 20, 4402 ± 4408 Walking Kit (Clontech). The DNA was sequenced and bioinformatically analysed. In an eort to map the precise position of the transcription start site, a primer extension reaction was performed.
Next we analysed the putative gene structure of CDCP1. The intron/exon boundaries were determined by direct sequencing of PCR products ampli®ed from human genomic DNA as well as Colo 205 cDNA (ATCC: CCL-222) using intron spanning primers. A total of eight exons were identi®ed (Figure 2) .
The chromosomal localization of the human CDCP1 gene was studied using a double target FISH assay on human metaphase chromosomes. The two DNA probes CDCP1 and the 3pter speci®c probe B47a2 were co-hybridized on metaphases from two normal individuals. The majority of the chosen metaphases showed signals on one or both chromatids in the region p21-p23 of chromosome 3 as visualized by the co-localization of the B47a2 (TRITC) on the same chromosomal arm (Figure 3 ). This is very interesting because CDCP1 shows an overexpression in an area usually associated with allele loss in other human tumors (Mitelman et al., 1997) .
Northern blot hybridizations were performed to determine the transcript length and to study the transcription pattern of CDCP1 in dierent tissues and cell lines. Northern blot analysis revealed an RNA transcript of approximately 6 kb in several tissues and cell lines examined ( Figure 4 ). Hybridization of blots with eight dierent cancer cell lines shows a transcript of the novel gene in colon adenocarcinoma SW480, lung carcinoma cells A549 and K-562, a chronic myelogenous leukemia cell line ( Figure 4a ). To further characterize the transcription pattern of CDCP1, multiple tissue Northerns from normal and cancer tissues were hybridized and showed a very heterogeneous transcription pro®le. Highest transcription level was found in samples derived from colon cancer tumors whereas RNA from normal colon tissue shows moderate expression only ( Figure 4b ). Furthermore analysis of normal tissues gave, with the exception of pancreas, weak positive signals in esophagus, stomach, rectum, prostate, placenta and peripheral blood lymphocytes (PBL). However, it should be considered that these ®lters contain RNA derived from whole tissue sections and therefore may contain transcriptional informations of in®ltrating cells such as lymphocytes, ®broblasts and endothelial cells derived from blood vessels as described by Hanahan and Weinberg (2000) . To compare the transcriptional patterns of CDCP1 between dierent human cancer and normal tissues as well as within dierent cell lines, real time RT ± PCR was performed. Ampli®cations of human GAPDH, û-tubulin and/or û-actin cDNA of comparable size were used as internal standards to normalize expression values of CDCP1 mRNA ( Figure  5a,b) . The results recon®rm the expression data obtained by Northern analysis showing highest expression of CDCP1 in colon and lung adenocarcinoma. Low expression can be observed in normal colon, lung, testis and invasive ductal carcinomas (IDC). Since the heterogeneous nature of tissue samples often makes interpretation dicult, laser capture microdissection (LCM) was used to isolate homogenous populations of cancer cells from clinical tissue specimens for real time quantitative RT ± PCR analysis (Bornstein et al., 1998) . Enriched cancer cells from tumor tissues gave clear evidence that CDCP1 is highly expressed in all tumor Figure 1 Approximately 1300 IMAGE clones of known and unknown genes together with 120 selected ESTs, derived from the subtracted lung cancer library, were arrayed on glass slides. These cDNA chips were hybridized with Cy3 labeled cDNA either from individual normal tissues or tumor tissues or cell lines each together with a Cy5 labeled cDNA derived from a mixture of 10 normal tissues (bone marrow, heart, kidney, liver, lung, pancreas, skeletal muscle, spleen, thymus, placenta). The Cy5 signal was used for normalizing intensities. Figure 2 Nucleotide sequence of the coding and 5'¯anking region, and the deduced amino acid sequence of the CDCP1 gene. Using RNA isolated from the non small lung cell carcinoma cell line Calu 6 (ATCC: HTB-56), a LoneLinker cDNA library was constructed (Abe, 1992) . PCR ampli®cation with a CDCP1 speci®c primer (5'-AGTCCATGTGAACAAGTTGAGG-3') and a LoneLinker speci®c primer (5'-GAGATATTAGAATTCTACTC-3'), resulted in a 6 kb fragment. DNA containing a portion of the promoter region for the human CDCP1 gene was isolated using a human Promoter Finder DNA Walking Kit (Clontech) and the gene speci®c primer 5'-AGAACCCCTAGCAGTGCGATAGAGAC-3'. To determine the precise transcription start side primer extension (Sambrook et al., 1989) was performed using 25 mg total RNA from the human cell line Colo 205 as template. A 35 Slabeled sequencing ladder generated from a 363 bp PCR fragment (nt 800 ± 1162) was used as a length standard. The elongation of the 32 P-labeled reverse primer (positioned from nt 209 ± 183) resulted in a fragment of 209 nucleotides in length (data not shown). The initiation site of transcription,¯anked by a cap signal consensus (GCAGCTGC), as well as the Kozak-type start of translation (ATG) and stop codon (TAA) are marked with gray boxes. The positions of the introns are marked by black triangles. The upstream genomic sequence contains no TATA or CCAAT box, however a GC-box as well as recognition sites for the rare cutter enzyme BssHII are indicated in the upstream region and in exon 1. Together with the fact that the 5' region has a GC content over 60% indicates that CDCP1 contains a CpG island. The putative transmembrane-spanning domain is underlined and 12 potential Nglycosylation sites are indicated in bold italic CDCP1 gene in human colorectal cancer M Scherl-Mostageer et al Figure 3 Chromosomal localization of human CDCP1. The human CDCP1 probe (nt 281 ± 2532) was nick translated with digoxigenin 711-dUTP and hybridized in situ at a ®nal concentration of 20 ng/ml together with biotin labeled B47a2 (kindly provided by Dr L Kearney) located at the sub-telomeric region of chromosome arm 3p (Knight et al., 1997) to metaphases from two normal individuals (Lichter et al., 1988) . The hybridized digoxigenin probes were detected with sheep anti dig (Boehringer Mannheim, Germany) and rabbit anti sheep antibodies both labeled with FITC. The biotin labeled probes were detected with mouse anti biotin and rabbit anti mouse (TRITC), and then counter-stained with DAPI. The CDCP1 gene could be assigned to the chromosomal region 3p21-23 Figure 4 Expression analysis of CDCP1. Commercially available Northern blots containing 2 mg of mRNA from cell lines (a) and human tissues (b), were hybridized with a 317 bp cDNA fragment from the coding region of CDCP1 (spanning nucleotide 827 ± 1144). All DNA fragments were 32 P-labeled by random priming using the RTS Prime DNA labeling System (Gibco ± BRL). Lanes are (HL-60) Promyelocytic leukemia, (S3) HeLa cell, (K-562) Chronic myelogenous leukemia, (MOLT-4) Lymphoblastic leukemia, (Raji) Burkitt's lymphoma Raji, (SW480) Colorectal adenocarcinoma, (A549) Lung carcinoma and (G361) Melanoma. Arrows indicate the position of the 6 kb CDCP1-transcript. High levels of CDCP1 mRNA are observed in SW480, A549 and in colon cancer tissue. Low level of CDCP1 expression is observed in normal colon, normal stomach, normal rectal and tumor tissue. No expression is detected in other cell lines examined including HeLa, Burkitt's lymphoma and melanoma G361 Figure 5 Real time quantitative RT ± PCR of CDCP1. 3 mg of total RNA isolated from dierent tissues and cell lines were used for ®rst strand cDNA synthesis with an oligo dT primer (Promega) according to manufacturer's recommendations (Gibco ± BRL). 1/50 of the RT reaction was used as a template for cDNA ampli®cation with CDCP1 speci®c primers 5'-TTGAATTC-ACTGTGTGGAGCC-3' and 5'-TGCAGGCAA-CAGTGATGTC-3' together with the labeled probe 5'-6-carboxyuorescein-ATTGGCCTTCCTTAGGCTGGCTAC-6 -carboxytetramethyl-rhodamine-3' designed to anneal to unique sequences found in the 3' untranslated region of the CDCP1 mRNA. Real time PCR was performed using PRISM 7700, ABI System. Expression pro®les were determined in dierent cancer and normal tissues normalized to û-actin (a) and û-tubulin (b) mRNA. Also expression pro®les from microdissected colon cancer biopsies (black bars) compared to controls from normal colon samples (white bars) as well as from colon cancer cell lines (gray bars) normalized to GAPDH mRNA were performed (c). CDCP1 is signi®cantly upregulated in colon adenocarcinoma and moderately expressed in lung cancer and mamma IDC compared to normal tissues CDCP1 gene in human colorectal cancer M Scherl-Mostageer et al cells of colon cancer patients. In summary the data correlate well with the results obtained from Northern blots and con®rm that CDCP1 is signi®cantly upregulated in colon cancer (Figure 5c ). Bearing in mind the fact that CDCP1 maps to 3p21-23, a region that has been shown to be deleted in other human tumors, CDCP1 is potentially an interesting protein, because it could be predicted that a gene within this region is down regulated. However, whether CDCP1 is ampli®ed in colon cancer needs to be veri®ed by additional genomic studies. The complete nucleotide sequence of the coding region as well as 200 bp genomic region upstream of the transcription start site and the predicted amino acid sequence are given in Figure 2 . The cap site motif CGCAGCTGC indicates the transcription initiation site (Bucher, 1990) . The derived CDCP1 mRNA is 5952 nucleotide in length, excluding the poly A tail. The open reading frame (ORF) starts with the Kozaktype (GTCATGG) translation initiation site (Kozak, 1987) and ends at a stop codon at position 2591 ± 2593. The 200 bp upstream sequence to the proposed transcription start site of CDCP1 does not contain a TATA or a CCAAT box. However, a GC-box as well as recognition sites for the rare cutter enzyme BssHII were found in the upstream region and in exon 1. The fact that the 5' region has a CG content over 60% indicates that CDCP1 contains a CpG island (Bird, 1986; Cross et al., 2000) .
The ORF extends 2511 bp and encodes a protein of 836 amino acids. The deduced primary amino acid structure of the CDCP1 protein is shown in Figure 6 . Statistical analysis of the amino acid sequence reveals that the CDCP1 protein exhibits a transmembrane domain (amino acid residues 666 ± 691). A signal peptide (residues 1 ± 29) was identi®ed which is characteristically for many membrane proteins (Wickner and Lodish, 1985) . Twelve potential sites for N-glycosylation in the predicted CDCP1 protein sequence at position 39, 122, 180, 205 213, 270, 310, 339, 386, 477, 512 and 577 are located exclusively in the extracellular domain.
Three potential CUB domains (Bork and Beckmann, 1993; Romero et al., 1997) were identi®ed in the Nterminal part (approximately residue ranges 220 ± 350, 425 ± 535 and 545 ± 660) using sequence comparison, fold recognition and secondary structure prediction. CUB domains are structurally related to immunoglobulin domains. CUB domain-containing proteins are components and activators of the mammalian complement system as well as proteases responsible for the activation of trypsinogen and cleavage of collagen and ®bronectin. Other members are the vertebrate bone morphogenetic protein (BMP-1) and proteins involved in cell adhesion or interacting with the extracellular matrix. A majority of CUB domain-containing proteins is developmentally regulated (Bork and Beckmann, 1993) . A recent publication demonstrates, that CUB domain containing proteins are the most dierentially regulated proteins in C. elegans larval development (Gerstein and Jansen, 2000) . Since genes that play key functions in embryonic development often ful®l analogous roles in cancer (Bhatia-Gaur et al., 1999; Cangi et al., 2000) , one could speculate that upregulation of CDCP1 may modulate the cell substrate adhesion or the interaction with the extracellular matrix. A hexalysine stretch (692 ± 697) may confer capability for unspeci®c electrostatic interactions and thus reinforce speci®c interactions possibly performed by the remainder of the intracellular part. Taken together, particularly in view of the function performed by other CUB domain containing proteins, one may speculate that CDCP1 is a transmembrane protein playing a role in communication, interaction or signaling with extracellular components or ligands in a way that is not yet understood. Although CDCP1 is upregulated in colon and lung cancer, that does not necessarily imply its role in oncogenesis, since dierential gene expression could simply be an eect and not a cause of the carcinogenic process. Further investigations have to be done to elucidate the physiological function of this novel protein. Figure 6 The modular architecture of CDCP1. Low complexity regions and regions of compositional bias of the protein were identi®ed using SEG (Wootton and Federhen, 1996) and BIASDB. The transmembrane segment was identi®ed using SAPS (Brendel et al., 1992) (statistical analysis of protein sequences, part of bioSCOUT TM ) as well as HMMTOP (Tusnady and Simon, 1998) and TMHMM (Sonnhammer et al., 1998) . The signal peptide was identi®ed using the SignalP program (Nielsen et al., 1997) . Putative N-glycosylation sites were identi®ed via a ProSearch (bioSCOUT TM ) of the PROSITE database of regular expressions. For inference of the domain structure the pattern databases Pfam (Bateman et al., 2000) and SMART (Schultz et al., 2000) were used. The SMART`schnipsel' database was instrumental in identifying the ®rst CUB domain. Fold recognition (ProCeryon software package from ProCeryon Biosciences) was employed for validation of the marginal sequence homology to known CUB domains in case of the second and third CUB domain. Secondary structure prediction was performed with the DSC program (King and Sternberg, 1996) . The translation shows the product of the 836 AA long open reading frame. The extracellular domain is shown in gray, the transmembrane helix (TM) in black and the intracellular region of CDCP1 protein in white. Cross-hatched boxes indicate three CUB domains in the extracellular part. Asterisks indicate the location of 12 potential N-glycosylation sites, the arrow indicates a hexalysine stretch and a proline rich region is shown as a hatched box L Wightman for critically reading the manuscript. Last but not least we want to thank KK Wilgenbus, G Adolf and M Baccarini for helpful discussions.
Note added in proof
The novel cDNA sequence, published here has been submitted to the GenBank sequence data bank (the accession number is AY026461). We would also like to mention that while writing this publication two other sequences, overlapping with our gene were submitted to the public database (AK026622 and AK023834).
